

27. Bilal A, Yi F, Gonzalez GR, et al. Effects of newer anti-hyperglycemic agents on cardiovascular outcomes in older adults: Systematic review and meta-analysis. *J Diabetes Complications*. 2024 Aug;38(8):108783.
28. Ledesma G, Umpierrez GE, Morley JE, et al. Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial. *Diabetes Obes Metab*. 2019 Nov;21(11):2465-2473.
29. Doucet J, Chacra A, Maheux P, et al. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. *Curr Med Res Opin*. 2011 Apr;27(4):863-9.
30. Karyekar CS, Ravichandran S, Allen E, et al. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus. *Clin Interv Aging*. 2013;8:419-30.
31. Iqbal N, Allen E, Öhman P. Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥ 65 years) with type 2 diabetes. *Clin Interv Aging*. 2014 Sep 4;9:1479-87.
32. Pratley RE, Rosenstock J, Pi-Sunyer FX, Banerji MA, Schweizer A, Couturier A, Dejager S. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. *Diabetes Care*. 2007 Dec;30(12):3017-22.
33. Round EM, Engel SS, Golm GT, et al. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. *Drugs Aging*. 2014 Mar;31(3):203-14.
34. Barnett AH, Huisman H, Jones R, et al. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2013 Oct 26;382(9902):1413-23.
35. Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. *Diabetes Obes Metab*. 2013 Oct;15(10):906-14.
36. Nagao M, Sasaki J, Sugihara H, et al. STREAM Study Investigators. Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study. *Sci Rep*. 2023 Jan 4;13(1):134.
37. Wang Y, Shao X, Liu Z. Efficacy and safety of sodium-glucose co-transporter 2 inhibitors in the elderly versus non-elderly patients with type 2 diabetes mellitus: a meta-analysis. *Endocr J*. 2022 Jun 28;69(6):669-679.
38. Pratley R, Dagogo-Jack S, Charbonnel B, et al. Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies. *Diabetes Obes Metab*. 2020 Dec;22(12):2276-2286.
39. Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. *Hosp Pract (1995)*. 2013 Apr;41(2):72-84.
40. Sinclair AJ, Bode B, Harris S, et al. Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. *J Am Geriatr Soc*. 2016 Mar;64(3):543-52.
41. Aldafas R, Crabtree T, Alkharaji M, et al. Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis. *Age Ageing*. 2024 Jan 2;53(1):afad254.
42. Pasqualotto E, Rodrigues FR, E Silva Ribeiro GB, et al. The effect of sodium-glucose transporter 2 inhibitors on stroke in patients with type 2 diabetes: A meta-analysis. *J Stroke Cerebrovasc Dis*. 2024 Aug;33(8):107730.
43. Pan SY, Su EL, Huang CJ, et al. Evaluation of glucose-lowering medications in older people: a comprehensive systematic review and network meta-analysis of randomized controlled trials. *Age Ageing*. 2024 Aug 6;53(8):afae175.
44. Kvapil M, Břízová L, Nováková M. Léčba diabetu u starších pacientů. *Farmakoter Revue* 2023;8(1):1-5.
45. Kvapil M, Nováková M. Antidiabetika v ordinaci internisty. *Acta medicae*. 2022;14:in press.
46. Nováková M, Kvapil M. Kardiovaskulární bezpečnost antidiabetik u seniorů. *Svět prakt. medicíny*. 2022;4:34-35.



20.

interní
medicína
pro praxi

6.-7. 3. 2025
OLOMOUC



SAVE
THE
DATE

Průběžně aktualizovaný
program a registrace:
www.kongresinterna.cz

PŘIPRAVOVANÉ TEMATICKÉ BLOKY:

- Komplikace imunoterapie u onkologického pacienta
- Racionální ATB terapie
- Alergologie
- Case Based Learning
- Blok ambulantních internistů
- Kardiovaskulární onemocnění
- Perspektivy medicíny

MÍSTO KONÁNÍ: **CLARION
CONGRESS HOTEL OLOMOUC**
Jeremenkova 36

